Aquinnah Pharmaceuticals Receives $5M in Private Equity Funding

Aquinnah Pharmaceuticals, a Cambridge, MA-based developer of therapies to slow the progression of ALS and other neurodegenerative diseases, received $5M in private equity funding.

Takeda Pharmaceutical Company made the investment.

The company has assembled a world-class team of drug developers and an exceptional Scientific Advisory Board in the fields of Amyotrophic Lateral Sclerosis (ALS), protein and RNA regulation, and neurodegenerative diseases.

Led by President and CEO Glenn Larsen, Ph.D., and co-founder Benjamin Wolozin, M.D., Ph.D., Aquinnah provides a technology platform that targets pathological protein complexes which are found in the brain of the majority of patients and thus believed to drive the progression of ALS (Amyotrophic Lateral Sclerosis) also known as Lou Gehrig’s disease.

Join the discussion